The Economic Data calendar for the week of the 8th of August through the 12th of August is full of critical releases and events. Here is a snapshot of some of the headline numbers that we will be focused on.
Takeaway: Current Investing Ideas: HOLX, HBI, LAZ, FL, TIF, WAB, ZBH, UUP, LMT, GLD, TLT
Below are our analysts’ new updates on our eleven current high conviction long and short ideas. As a reminder, if nothing material has changed in the past week which would affect a particular idea, our analyst has noted this.
Please note that we added PowerShares DB US Dollar Index Bullish Fund (UUP) to the long side of Investing Ideas and removed Junk Bonds (JNK), Dunkin' Brands (DNKN), Allscripts Healthcare Solutions (MDRX) and Treasury Inflation-Protected Securities (TIP). We will send Hedgeye CEO Keith McCullough's refreshed levels for our high-conviction Investing Ideas in a seperate email.
We made some changes in this week's edition of Investing Ideas, with the removal of Junk Bonds (JNK) on the short side and Treasury Inflation-Protected Securities (TIP) on the long-side.
With the epic move in ten-year yields to all-time lows, corporate credit spreads (JNK) have floated off the “risk-free” rate. The pull-back in cross-asset volatility from the February highs in the VIX, OVX (oil volatility index), and the MOVE Index (Treasury volatility index), likely exacerbated the tightening in spreads.
The credit cycle WILL cycle, and deterioration in consumer and corporate credit remains an important Hedgeye Macro theme. This week the Q2 Fed Senior Loan Officer Survey was released which confirmed deterioration in credit conditions (see the chart below for our credit cycle indicator; the chart is busy but it’s worth a hard look).
Our team’s macro process is both fundamental and top-down, and we get the top-down signals in real-time. The bottom-line is that both the CRB Commodities Index and crude oil have recently broken down from a quantitative risk management perspective. While this is a key factor contributing to our recent addition of the PowerShares DB US Dollar Index Bullish Fund (UUP), it also signals that TIP does not have as much upside as we thought. As Keith McCullough wrote to subscribers this week:
“Changing my mind on longer-term longs has happened infrequently this year, but it should happen. That’s how the game goes.”
Getting out of a position if it’s not working is much more prudent than stubbornly sticking with it when your process signals otherwise.
Back to growth ... we’ll refrain from commenting on Friday’s headline non-farm payrolls number in isolation, and rather offer some perspective on the cyclical nature of the non-farm payroll data series (you’ve heard it before):
To view our analyst's original report on Hanesbrands click here.
Hanesbrands (HBI) reported 2Q earnings this week. Salesmanship was on another level this quarter, as Richard Knoll took his 10-year victory lap before officially handing the reins over to Gerald Evans. But, salesmanship on the conference call can't mask lack of sales dollars on the P&L, as HBI missed sales expectations for the 8th time in 10 quarters, and posted the 3rd worst organic growth rate since the company became a serial acquirer. Margins showed the first crack we’ve seen in over 2 years – down 75bps Y/Y as competition and the effects of bloated inventories began to rear their heads. Despite all the talk about inventory reduction actions, core inventory grew 11% on -3% sales growth – even more troubling when we consider tepid demand from the company’s wholesale partners.
Even with some recent weakness in the stock, we like the short even more after this print. All in, we think that HBI has another 40% downside until the risk/reward looks more balanced in our model, with the possibility of an even bigger move in the worst case scenario.
To view our analyst's original report on Zimmer Biomet click here.
As we detailed in our Healthcare Themes deck this past month, the US medical economy is on the edge of a massive deceleration. July Helathcare employment, which is a lagging factor, slowed again. Next week, we will get the leading/coincident indicator of demand in the Job Openings and Labor Turnover series on August 10th.
Since growth in insured medical consumers has slowed to 1.5% currently, and managed care payors are withdrawing from Obamacare Public Exchange business, we expect growth in this series to deteriorate further. Hospital admissions continue to slow through 2Q16, with operators cutting guidance.
While Orthopedic and surgical demand appears positive, we still expect declines to emerge and pricing to accelerate to the downside. The CJR has already hit post-acute care, reducing admissions by 40% anecdotally across joint replacements. The next step, again anecdotally, will be to pressure device costs.
To view our analyst's original report on Hologic click here.
In the latest data from MQSA, which has recently begun reporting placements of Digital Breast Tomosynthesis systems, it would appear that growth is slowing and Hologic's (HOLX) share of the incremental facility is dropping. According to the data, the market added 109 facilities in July after adding 107 in June, this conversion pace is similar to the 2D adoption curve post peak.
As it relates to our data, which shows 33 and 22 facilities converting to Hologic, the implication is that Hologic is losing out. In fact when we spoke to a former sales representative who sold mammography for Hologic, the benefits of one manufacturer over the other were scant at best. Going forward, we expect a slowing US Medical economy, as forecast using the slowing number of insured medical consumers, will provide the second leg of disappointing growth for our thesis.
Next Wednesday on August 10th BLS will update the JOLTS data for healthcare, a time series tightly correlated with market growth. We expect a declining number sequentially and slowing overall which will impact Hologic’s Diagnostic segment, the standout this past quarter.
To view our analyst's original report on Lazard click here.
No update on Lazard (LAZ) this week but Hedgeye Financials analyst Jonathan Casteleyn reiterates his short call on the company.
To view our analyst's original report on Tiffany click here.
The government released June PCE data this week. As it relates to Tiffany (TIF), we again are looking at the spend in the luxury sector. Real luxury spending went negative in May for the first time since 2011 and the June number, which showed a slight inflection (lower highs and lower lows), was in negative territory once again. That marks the first time we’ve seen negative spending data at the high-end.
The comp sales trajectory has been one of the worst we’ve seen in retail at Tiffany, and some may argue that the company is facing easy compares. But we think that’s a simplistic analysis, given the weakness we are starting to see in the category. We think the negative macro pressure here will compound the already big demand issues TIF is facing. That means… more sales and earnings surprises to the downside.
To view our analyst's original report on Foot Locker click here.
Diving in on what the Nike Wholesale and DTC dynamics mean for Foot Locker (FL), we outlined last week that given the likely Nike US wholesale growth scenario, FL needs an incremental $200mm from the likes of UA and AdiBok to hit current Consensus Estimates. This means that UA would need to grow FW 60% and AdiBok 20% with 50% of that growth coming from wholesale with the over arching assumption that FL captures 40% of the incremental share from each of the brands.
The only problem with those type of growth and channel assumptions is that Nike isn’t the only brand navigating around its wholesale partners. AdiBok is the worst offender with 70% of its incremental growth over the past 4 years coming from the direct channel. UA is at 32%, and we think FW growth for UA is more heavily weighted to the DTC channel. That means from here, the likes of AdiBok and Under Armour would need to take share from NKE, allocate over 40% of its wholesale growth to FL, and (not or) redirect a portion of its more profitable retail growth to the wholesale channel. A lot has to go right for that to happen.
To view our analyst's original report on Wabtec click here.
No update on Wabtec (WAB) but Hedgeye Industrials analyst Jay Van Sciver reiterates his short call. Hedgeye CEO Keith McCullough had this to say about the company in a Real-Time Alerts signal sent earlier this week:
"Again, our Best Ideas research list of SELL ideas is a lot longer than my live SELL list in Real-Time Alerts. Main reason for that = patience. I realize consensus is chasing US Equity Beta, so I'm happy to wait and watch for selling opportunities.
Wabtec (WAB) has been an excellent SELL idea by Jay Van Sciver. We like it when we don't like a stock and it goes down when the market is going up. Jay's most recent comment on WAB was:
"We will let others summarize the WAB quarter, but would note that our WAB thesis continues to play out reasonably well. We would caution longs that this is only the third quarter of down freight revenue, and both railcar and locomotive deliveries in the quarter remained well above likely ‘normalized’ demand."
To Patient Bears,
To view our analyst's original report on Lockheed Martin click here.
On Tuesday, the Air Force declared that Lockheed Martin's (LMT) F-35A has officially achieved “Initial Operational Capability” (IOC). Specifically, this means that the Air Force now has "an operational squadron of 12-24 aircraft with Airmen who are trained, manned, and equipped to conduct basic Close Air Support (CAS), Interdiction, and limited Suppression and Destruction of Enemy Air Defense (SEAD/DEAD) operations in a contested environment.”
It is hard to overstate the importance of this milestone for the largest Defense acquisition program in history. There is now a clear sense of momentum for the program and the operational milestones are coming in bunches. The commander of Air Combat Command declared that he would be getting the F-35A into operations either against ISIS or to Europe in the “near future.” The Marines now have two operational squadrons and with the first deploying next year to Iwakuni, Japan for potential operations in Korea. This week also saw the Navy beginning its third and final phase of developmental testing at sea on the George Washington.
With operational flight data now available, speculative criticism of operational capability has almost completely withered away. Concern for costs is still present but it is based on the volume of jets needed/desired (2,443 for US) rather than the unit cost of $80-85M for the A (B&C models cost 10-15% more).
Our inimitable, in-house cartoonist Bob Rich is on a much-deserved summer vacation. While he kicks back and relaxes, we're going into the Hedgeye Vault and highlighting some of his best work. After Friday's Jobs Report "beat" analyst expectations, Hedgeye CEO Keith McCullough wrote, "After going from hawkish to dovish to hawkish to dovish to hawkish, this Jobs print keeps Federal Reserve hawkish." Here's another audience favorite ... Blast off!
Get The Macro Show and the Early Look now for only $29.95/month – a savings of 57% – with the Hedgeye Student Discount! In addition to those daily macro insights, you'll receive exclusive content tailor-made to augment what you learn in the classroom. Must be a current college or university student to qualify.
Takeaway: Please note we are removing MDRX from Investing Ideas (short side) today.
Hedgeye CEO Keith McCullough is removing Allscripts Healthcare Solutions (MDRX) from Investing Ideas today. Below is an excerpt from an institutional research note written by Hedgeye Healthcare analysts Tom Tobin and Andrew Freedman in which they lay out their outlook for the stock and weigh the current upside and downside.
Allscripts (MDRX) reported 2Q16 Sales of $397 million and Adjusted EBITDA of $69.5 million, with both missing consensus estimates of $403.5 million and $72.7 million, respectively. Driving the miss was a lower revenue contribution from Netsmart of $43 million versus $50 million consensus, and disappointing organic sales growth of +0.6% YoY despite strong bookings performance. The Netsmart joint-venture and financial consolidation masked what would have been a larger miss, with 2Q16 core Allscripts revenue of $353.6 million missing pre-Netsmart consensus sales estimates of $363.0 million, and our estimate of $357.8 million. Note that 1H16 organic revenue growth of +1.8% YoY is below management's guidance for core Allscripts growth of 3-5%, and with guidance left unchangedorganic growth will have to accelerate to +6% YoY in 2H16 to hit consensus numbers and management's guidance. This compares to our estimate of +3.5% sales growth in 2H16 and expectations the company will continue to miss estimates like they have for the past 3 quarters.
Non-GAAP EPS of $0.14 was in-line with consensus and slightly above our estimate of $0.13. However, we would highlight that a combination of a higher R&D capitalization rate for Netsmart and an increase in stock-based compensationresulted in Non-GAAP R&D expense that was down sequentially, which provided a 190bps sequential tailwind to operating margins in 2Q16.
Bookings were the big positive surprise in the quarter, but were somewhat anomalous even considering seasonality. Total bookings excluding Netsmart were +22% YoY with mix favoring higher margin software delivery bookings that were up +44% YoY. Meanwhile, Client Services bookings were down -6% YoY, -26% QoQand marks a deviation from a 3 quarter trend where the mix shift had favored client services due to cross-selling of hosting and other outsourcing services to existing clients. We have argued that the rate of 2H15 client services bookings was not sustainable as they max out wallet share with their largest clients. Total backlog growth excluding Netsmart was +5% YoY, which is down from +5.6% YoY in 1Q16 and +6.4% in 4Q15, and in-line with our model implying higher churn given our lower bookings estimate.
We have a hard time understanding the drivers of the strength in software delivery given reported deal flow compared to previous periods and our assessment of a slowing market, which we believe to be valid. Despite the many questions on the conference call, management would not provide transparency into the number. We question the impact a single deal may have had on the number, specifically the strategic agreement with OptumCare to rollout the Touchworks EHR and Practice Management system across their network of providers. OptumCare was the "commercial partner" tied to the warrant issuance for 4.1 million shares, and while it appears we were wrong to be skeptical about its near-term impact on bookings, we were right in that it was an atypical structure and more strategic in nature.
"It's a long term, it's a strategic deal so you can imagine it doesn't look like a typical agreement. It's not a typical agreement. This is the platform which we expect to, over time, translate to a significant sized relationship between the two entities." -2Q16 Earnings Call
Near-term revenue impact from the deal will likely be modest, and while we have more to learn about OptumCare, it seems there may be hurdles to getting physicians to adopt. Additionally, we place less value on the deal as they had to tradeoff economics in the company to close it.
"...we're going to be methodical and make sure we get it right, get it plugged into the rest of their standardized platform and that they have the time to educate their providers on the benefit of the standard platform too. So they're not — nobody is interested in jamming it down anybody's throat." -2Q16 Earnings Call
Despite management's positive commentary around improvements in Touchworks and the OptumCare deal, we view it as too little too late, with recent market share losses irreversible, especially at the large IDNs. Additionally, while we appreciate that Black Book "deploys one of the most statistically significant survey techniques in the industry", the results run counter to market trends. We would like to see the characteristics and details of the survey population ourselves.
We spoke to a 30-year CIO at one of the largest IDN's in Michigan who is currently migrating away from a combination of Touchworks and Pro EHR to Paul Black's alma mater who had the following to say about Allscripts:
We like the risk/reward on the short side given back-end loaded sales guidance, at a time where we face the most difficult bookings comparisons of the year. We don't view strength in software delivery bookings as sustainable, which we believe was confirmed by management's guidance related to bookings mix in future quarters and for a return to normalized software delivery gross margin. Meanwhile, Netsmart acquisition brings more accounting shenanigans and is a low quality, highly levered, short-term "fix" to management's growth problems.
Keith and I have spent much of the past four weeks on the road visiting with existing and prospective clients the world over (~35 meetings in total). As always, the buysider-to-[former]-buysider nature of such dialogues allows for a higher order of debate and critical thinking that both parties typically find invaluable.
Below is a summary of what I found to be the most important, thoughtful and/or consistent topics of discussion, organized by theme (all quotations paraphrased); hopefully you find it helpful as well. Any associated charts, research notes or presentations are hyperlinked below for ease of review.
Hopefully you’ve found these discussions helpful. As always, please feel free to reply with any follow-up questions.
Best of luck out there incorporating the aforementioned factors into your existing and respective research and risk management frameworks.
Happy Summer Friday,
Carney did his best to devalue the purchasing power of The People yesterday (a little “market security” in exchange for what was great drive for the UK consumer economy in 2015, #StrongPound) and got GBP/USD down to $1.31 while blasting the 10yr Gilt Yield down to 0.63% where it’s holding this morning, down -14bps month-over-month.
Quite the bear of deflation re-developing here; shall they call it Commodities “Ex-Energy”? I call this a bearish TREND @Hedgeye with an old wall of resistance up at CRB Index 185 with no legitimate support to 165.
If you don’t have growth (we’re all in the 1% GDP now) and inflation is deflating, what do you have? A: Long Bond Bulls. A bad jobs report gets me 1.40% on the UST 10yr; a “good one” might get me 1.60%; all the while JGBs and Bunds not moving like they did earlier in the week; watching those closely.
|CASH||US EQUITIES||INTL EQUITIES||COMMODITIES||FIXED INCOME||INTL CURRENCIES|
|CASH||US EQUITIES||INTL EQUITIES||COMMODITIES||FIXED INCOME||INTL CURRENCIES|
To summarize our active ideas, long Gold (GLD) and long U.S. Dollar position (via PowerShares DB US Dollar Index Bullish Fund (UUP), netted out Friday, with gold catching a bid against a USD that got crushed on the report. (Part of the reason we added UUP to Investing Ideas was the expectation of a GDP print that may have sent a hawkish message to the market.) Think of Gold and the USD as a position against a basket of other currencies.
The good news for #GrowthSlowing bulls is that the Treasury rate curve will likely get pushed lower over the coming days as investors take stock of this week’s ugly data. That's good for Treasury Inflation-Protected Securities (TIP) and Long Bonds (TLT).
See update on GLD.
"I've never lost a game, I just ran out of time"
Daniel Murphy is leading the MLB in BA currently, he is hitting .358
Start receiving Hedgeye's Cartoon of the Day, an exclusive and humourous take on the market and the economy, delivered every morning to your inbox
By joining our email marketing list you agree to receive marketing emails from Hedgeye. You may unsubscribe at any time by clicking the unsubscribe link in one of the emails.